相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ABT-450: A Novel Protease Inhibitor for the Treatment of Hepatitis C Virus Infection
Ivan Gentile et al.
CURRENT MEDICINAL CHEMISTRY (2014)
ABT-450, Ritonavir, Ombitasvir, and Dasabuvir Achieves 97% and 100% Sustained Virologic Response With or Without Ribavirin in Treatment-Experienced Patients With HCV Genotype 1b Infection
Pietro Andreone et al.
GASTROENTEROLOGY (2014)
Liver Disease Progression in Hepatitis C Virus Carriers With Normal Alanine Aminotransferase Levels
Claudio Puoti et al.
HEPATOLOGY (2014)
Sofosbuvir and Ribavirin for Hepatitis C in Patients With HIV Coinfection
Mark S. Sulkowski et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2014)
Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A
David A. DeGoey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Importance of HCV genotype 1 subtypes for drug resistance and response to therapy
D. L. Wyles et al.
JOURNAL OF VIRAL HEPATITIS (2014)
Retreatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treatment of HCV with ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin
Jordan J. Feld et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Untreated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection
Nezam Afdhal et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with or without Ribavirin for HCV
Peter Ferenci et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1
Kris V. Kowdley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
ABT-450/r-Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Pharmacokinetics, Safety and Tolerability of Cyclosporine or Tacrolimus Following Coadministration of ABT-450/r, ABT-267 and ABT-333 in Healthy Subjects.
P. Badri et al.
TRANSPLANTATION (2014)
Hepatitis C virus NS5A inhibitors and drug resistance mutations
Shingo Nakamoto et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Exploratory Study of Oral Combination Antiviral Therapy for Hepatitis C
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Sofosbuvir for Previously Untreated Chronic Hepatitis C Infection
Eric Lawitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
IN VITRO COMBINATORY EFFECT OF HCV NS3/4A PROTEASE INHIBITOR ABT-450, NS5A INHIBITOR ABT-267, AND NON-NUCLEOSIDE NS5B POLYMERASE INHIBITOR ABT-333
T. Pilot-Matias et al.
JOURNAL OF HEPATOLOGY (2012)
SAFETY AND ANTIVIRAL ACTIVITY OF ABT-267, A NOVEL NS5A INHIBITOR, DURING 3-DAY MONOTHERAPY: FIRST STUDY IN HCV GENOTYPE-1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2012)
An Update on Treatment of Genotype 1 Chronic Hepatitis C Virus Infection: 2011 Practice Guideline by the American Association for the Study of Liver Diseases
Marc G. Ghany et al.
HEPATOLOGY (2011)
PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV NS5A INHIBITOR ABT-267 FOLLOWING SINGLE AND MULTIPLE DOSES IN HEALTHY ADULT VOLUNTEERS
E. O. Dumas et al.
JOURNAL OF HEPATOLOGY (2011)
GENOTYPIC AND PHENOTYPIC CHARACTERIZATION OF NS3 VARIANTS SELECTED IN HCV-INFECTED PATIENTS TREATED WITH ABT-450
T. Pilot-Matias et al.
JOURNAL OF HEPATOLOGY (2011)
Hepatitis C virus resistance to protease inhibitors
Philippe Halfon et al.
JOURNAL OF HEPATOLOGY (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Institute of Medicine Recommendations for The Prevention and Control of Hepatitis B and C
Abigail E. Mitchell et al.
HEPATOLOGY (2010)
PHARMACOKINETICS OF THE HCV POLYMERASE INHIBITOR ABT-333 IN US AND JAPANESE HEALTHY VOLUNTEERS
R. Menon et al.
JOURNAL OF HEPATOLOGY (2010)
RESISTANCE PROFILE OF ABT-333 AND RELATIONSHIP TO VIRAL LOAD DECREASE IN PATIENTS TREATED IN COMBINATION WITH PEG-INTERFERON AND RIBAVIRIN FOR 28 DAYS
T. Middleton et al.
JOURNAL OF HEPATOLOGY (2010)
Rapid Emergence of Protease Inhibitor Resistance in Hepatitis C Virus
Libin Rong et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Inhibitors of the Hepatitis C Virus RNA-Dependent RNA Polymerase NS5B
Megan H. Powdrill et al.
VIRUSES-BASEL (2010)
PHARMACOKINETICS, SAFETY AND TOLERABILITY OF THE HCV POLYMERASE INHIBITOR ABT-333 FOLLOWING MULTIPLE ASCENDING DOSES AND EFFECT OF CO-ADMINISTRATION OF KETOCONAZOLE IN HEALTHY SUBJECTS
R. Menon et al.
JOURNAL OF HEPATOLOGY (2009)
PRECLINICAL POTENCY, PHARMACOKINETIC AND ADME CHARACTERIZATION OF ABT-333, A NOVEL NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR
C. Maring et al.
JOURNAL OF HEPATOLOGY (2009)
Effect of Early versus Deferred Antiretroviral Therapy for HIV on Survival
Mari M. Kitahata et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Transplantation in the patient with hepatitis C
Beatriz Dominguez-Gil et al.
TRANSPLANT INTERNATIONAL (2009)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
The natural history of recurrent hepatitis C and what influences this
Edward J. Gane
LIVER TRANSPLANTATION (2008)
Self-reported hepatitis C virus antibody status and risk behavior in young injectors
Holly Hagan et al.
PUBLIC HEALTH REPORTS (2006)
Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients -: A randomized controlled trial
F Carrat et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2004)
Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons
RT Chung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients
FJ Torriani et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Incidence and predictors of severe liver fibrosis in human immunodeficiency virus-infected patients with chronic hepatitis C: A European collaborative study
L Martin-Carbonero et al.
CLINICAL INFECTIOUS DISEASES (2004)
Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: A cross-sectional analysis of the US adult AIDS clinical trials group
KE Sherman et al.
CLINICAL INFECTIOUS DISEASES (2002)
分享论文
